RBMX has been linked to chemoresistance in both T-cell lymphoma and small-cell lung cancer (75, 78), suggesting that it may affect treatment responses in esophageal cancer, particularly in platinum-resistant ESCC, by modulating DNA damage repair and apoptotic pathways, such as those involving the BCL2 family. This evidence concerns the gene BCL2 and esophageal cancer.